Extended Lymphadenectomy Does Not Improve DFS or OS Among Patients with Localised Muscle Invasive Bladder Cancer By Ogkologos - November 4, 2024 1877 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1011 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Adding Gedatolisib to Fulvestrant, with or without Palbociclib, Improves PFS in... March 17, 2026 First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Supports Targeting CLDN18.2... March 24, 2026 New on NCI’s Websites, March 2020 March 16, 2020 Therapy Rottweiler, known as Dogtor Loki, Is Delivering ‘Hero Healing Kits’... April 16, 2020 Load more HOT NEWS Rediscovered Drugs Hit Leukemia from Two Different Angles Science Surgery: ‘How are children’s cancers different from adult’s cancers?’ Results of Pivotal Study with BCMA Specific CAR T-Cell Therapy in... Single Mom Has To Beg For Rides To Doctor For Son...
